Annals of Emergency Medicine
Volume 45, Issue 6 , Pages 592-594 , June 2005

Shortness of Breath, Syncope, and Cardiac Arrest Caused by Systemic Mastocytosis

Received 9 November 2004 ,Revised 20 January 2005 ,Accepted 4 February 2005.

References 

  1. Horan RF, Austen KF. Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. J Invest Dermatol. 1991;96:S5–S14
  2. Golkar L, Bernhard JD. Mastocytosis. Lancet. 1997;349:1379–1385
  3. Duffy TP. Getting the story right. N Engl J Med. 1993;328:1333–1336
  4. Marone G, de Crescenzo G, Florio G, et al. Immunological modulation of human cardiac mast cells. Neurochem Res. 1999;24:1195–1202
  5. Gupta MK, Gupta P, Rezai F. Histamine: can it cause an acute coronary event?. Clin Cardiol. 2001;24:258–259
  6. Hedqvist P, Gautam N, Lindbom L. Interactions between leukotrienes and other inflammatory mediators/modulators in the microvasculature. Am J Respir Crit Care Med. 2000;161(Suppl):S117–S119
  7. Walch L, Norel X, Gascard J, et al. Functional studies of leukotriene receptors in vascular tissues. Am J Respir Crit Care Med. 2000;161(Suppl):S107–S111
  8. Valent P, Akin C, Sperr WR, et al. Mast cell proliferative disorders: current view on variants recognized by the World health Organization. Hematol Oncol Clin North Am. 2003;17:1227–1241
  9. Soter NA. Mastocytosis and the skin. Hematol Oncol Clin North Am. 2000;14:537–555
  10. Awad JA, Morrow JD, Roberts LJ. Detection of the major urinary metabolite of prostaglandin D2 in the circulation: demonstration of elevated levels of patients with disorders of systemic mast cell activation. J Allergy Clin Immunol. 1994;93:817–824
  11. Folco G, Rossoni G, Buccellati C, et al. Leukotrienes in cardiovascular diseases. Am J Respir Crit Care Med. 2000;161(Suppl):S112–S116
  12. Rich MW. Myocardial injury caused by an anaphylactic reaction to ampicillin/sulbactam in a patient with normal coronary arteries. Tex Heart Inst J. 1998;25:194–197
  13. Worobec AS. Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am. 2000;14:659–687
  14. Tolar J, Tope WD, Neglia JP. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. [letter] N Engl J Med. 2004;350:735–736
  15. Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet. 2003;362:535–536
  16. Hauswirth AW, Simonitsch-Klupp I, Uffmann M, et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res. 2004;28:249–257

 Funding and support: The authors report this study did not receive any outside funding or support.

PII: S0196-0644(05)00139-3

doi: 10.1016/j.annemergmed.2005.02.002

Annals of Emergency Medicine
Volume 45, Issue 6 , Pages 592-594 , June 2005

Article Tools

* Image Usage & Resolution